Live Breaking News & Updates on Simcere Pharmaceutical Company
Stay updated with breaking news from Simcere pharmaceutical company. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 DGAP-News: Evotec SE / Key word(s): Miscellaneous 19.04.2021 / 08:31 The issuer is solely responsible for the content of this announcement. EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ASSET EVT801 KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ( CMC ) EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES ....
Evotec AG: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ( CMC ) EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES HAMBURG, GERMANY / ACCESSWIRE / April 19, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered into both a licensing and master service agreement with Kazia Therapeutics Limited ( Kazia , ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialisation of Evotec s oncology project EVT801. ....
Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 – Health Technology Net digitalfacility.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitalfacility.com Daily Mail and Mail on Sunday newspapers.
Message : Required fields DGAP-News: Evotec SE / Key word(s): Miscellaneous Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 2021-04-19 / 08:31 The issuer is solely responsible for the content of this announcement. = . EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ASSET EVT801 . KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC . EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ( CMC ) . EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES ....
Kazia Therapeutics Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused drug development company, is pleased to share new data from its ongoing phase II study of paxalisib in glioblastoma, the most common and most aggressive form of primary brain cancer. The data is the subject of a poster presentation at the American Association of Cancer Research (AACR) Annual Meeting, which is being held virtually from 10-15 April 2021, and from 17-21 May 2021. Key Points Pharmacokinetic (PK) data, which shows how long paxalisib remains in the human body, strongly supports 60mg once daily dosing, confirming planned administration schedule for commercial launch. ....